PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and Marker Therapeutics (NASDAQ:MRKR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Institutional and Insider Ownership
22.4% of Marker Therapeutics shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares PTC Therapeutics and Marker Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PTC Therapeutics | -9.17% | N/A | -0.10% |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
Earnings & Valuation
This table compares PTC Therapeutics and Marker Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PTC Therapeutics | $1.73 billion | 2.94 | $682.64 million | ($1.40) | -43.55 |
| Marker Therapeutics | $3.55 million | 3.89 | -$12.16 million | ($0.41) | -2.02 |
PTC Therapeutics has higher revenue and earnings than Marker Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
PTC Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for PTC Therapeutics and Marker Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PTC Therapeutics | 1 | 3 | 10 | 1 | 2.73 |
| Marker Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
PTC Therapeutics currently has a consensus target price of $99.23, suggesting a potential upside of 62.75%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 1,106.85%. Given Marker Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than PTC Therapeutics.
Summary
Marker Therapeutics beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.
About PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
About Marker Therapeutics
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
